Sei Investments Co. Has $4.46 Million Stock Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Sei Investments Co. grew its stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 305.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 123,807 shares of the medical device company's stock after acquiring an additional 93,256 shares during the period. Sei Investments Co. owned 0.19% of Tandem Diabetes Care worth $4,460,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Arizona State Retirement System increased its position in Tandem Diabetes Care by 1.9% during the fourth quarter. Arizona State Retirement System now owns 18,961 shares of the medical device company's stock worth $683,000 after buying an additional 362 shares during the last quarter. Assetmark Inc. grew its stake in Tandem Diabetes Care by 77.5% in the 4th quarter. Assetmark Inc. now owns 1,225 shares of the medical device company's stock valued at $44,000 after buying an additional 535 shares during the last quarter. AlphaQuest LLC raised its holdings in Tandem Diabetes Care by 138.7% in the 4th quarter. AlphaQuest LLC now owns 931 shares of the medical device company's stock worth $34,000 after acquiring an additional 541 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Tandem Diabetes Care by 4.7% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 15,664 shares of the medical device company's stock valued at $664,000 after acquiring an additional 704 shares during the period. Finally, Jones Financial Companies Lllp boosted its holdings in Tandem Diabetes Care by 195.8% during the fourth quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company's stock valued at $41,000 after acquiring an additional 748 shares during the period.

Remove Ads

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on TNDM. Wells Fargo & Company restated an "equal weight" rating and set a $22.00 target price (down previously from $38.00) on shares of Tandem Diabetes Care in a research note on Monday, March 3rd. Citigroup downgraded shares of Tandem Diabetes Care from a "buy" rating to a "neutral" rating and reduced their price target for the company from $35.00 to $24.00 in a report on Tuesday, March 4th. Sanford C. Bernstein downgraded shares of Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and dropped their price objective for the stock from $35.00 to $25.00 in a report on Friday, February 28th. The Goldman Sachs Group decreased their target price on Tandem Diabetes Care from $42.00 to $24.00 and set a "neutral" rating on the stock in a research report on Monday, March 3rd. Finally, Barclays reduced their price objective on Tandem Diabetes Care from $60.00 to $53.00 and set an "overweight" rating for the company in a research report on Friday, February 28th. Eight research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company's stock. According to data from MarketBeat, Tandem Diabetes Care currently has an average rating of "Moderate Buy" and a consensus price target of $45.38.

Insider Transactions at Tandem Diabetes Care

In related news, COO Jean-Claude Kyrillos purchased 10,538 shares of Tandem Diabetes Care stock in a transaction dated Friday, March 7th. The shares were acquired at an average cost of $18.12 per share, for a total transaction of $190,948.56. Following the transaction, the chief operating officer now directly owns 10,538 shares of the company's stock, valued at approximately $190,948.56. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 2.20% of the stock is owned by company insiders.

Tandem Diabetes Care Price Performance

NASDAQ:TNDM traded down $0.03 during mid-day trading on Monday, reaching $16.85. 2,697,538 shares of the company were exchanged, compared to its average volume of 1,479,729. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29. The stock has a market cap of $1.12 billion, a PE ratio of -8.73 and a beta of 1.52. Tandem Diabetes Care, Inc. has a 12 month low of $15.76 and a 12 month high of $53.69. The company has a fifty day moving average of $25.96 and a 200 day moving average of $31.89.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.